Brucellosis is an infectious zoonosis caused by Brucella with clinical symptoms of wavy fever, fatigue,
and even invasion
of tissues and organs in the whole body, posing a serious threat to
public health around the world. Herein, a novel vertical flow immunoassay
based on Au@Pt nanoparticles (Au@PtNPs-VFIA) was established for detection
of Brucella IgG antibody in clinical serum samples.
The testing card of Au@PtNPs-VFIA was manufactured by printing the
purified Brucella LPS and goat antimouse IgG on the
nitrocellulose membrane as the test-spot or control-spot, respectively.
Au@PtNPs labeled with protein G (Au@PtNPs-prG) were concurrently employed
as detection probes presenting visible spots and catalysts mimicking
catalytic enzymes to catalyze the DAB substrate (H2O2 plus O-phenylenediamine) for deepening color development.
The testing procedure of Au@PtNPs-VFIA takes 2–3 min, and the
limit of detection (LOD) for Brucella antibody is
0.1 IU/mL, which is faster and more sensitive than that of Au@PtNP-based
lateral flow immunoassay (Au@PtNPs-LFIA: 15 min and 1.56 IU/mL, respectively).
By comparing with vertical flow immunoassay based on classic Au nanoparticles
(AuNPs-VFIA), the Au@PtNPs-VFIA is 32 times or 16 times more sensitive
with or without further development of DAB substrate catalysis. Au@PtNPs-VFIA
did not react with the serum samples of Gram-negative bacterium infections
but only weakly cross-reacted with diagnostic serum of Y. enterocolitica O9 infection. In detection of clinical
samples, Au@PtNPs-VFIA was validated for possessing 98.33% sensitivity,
100% specificity, and 99.17% accuracy, which were comparable with
or even better than those obtained by the Rose-Bengal plate agglutination
test, serological agglutination test, AuNPs-VFIA, and Au@PtNPs-LFIA.
Therefore, this newly developed Au@PtNPs-VFIA has potential for rapid,
ultrasensitive, and on-site diagnosis of human Brucellosis in clinics.